Edward Nash
Stock Analyst at Canaccord Genuity
(3.45)
# 928
Out of 5,132 analysts
79
Total ratings
47.22%
Success rate
6.51%
Average return
Main Sectors:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CORT Corcept Therapeutics | Maintains: Buy | $99 → $100 | $39.97 | +150.19% | 12 | Jan 23, 2026 | |
| VTYX Ventyx Biosciences | Downgrades: Hold | $16 → $14 | $13.97 | +0.21% | 8 | Jan 8, 2026 | |
| VERU Veru Inc. | Initiates: Buy | $25 | $2.29 | +991.70% | 1 | Dec 18, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $526 → $587 | $464.71 | +26.32% | 12 | Nov 13, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $106 → $107 | $29.00 | +268.97% | 2 | Nov 12, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $28 | $5.06 | +453.36% | 2 | Oct 2, 2025 | |
| IVA Inventiva | Maintains: Buy | $20 | $6.17 | +224.15% | 3 | Sep 30, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $62 | $22.97 | +169.92% | 3 | Sep 17, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $45 → $47 | $27.82 | +68.94% | 10 | Apr 10, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 | $1.24 | +625.81% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $1.11 | +260.36% | 2 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $67.78 | +31.31% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $1.03 | +676.70% | 3 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $3.84 | +342.71% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $3.24 | -38.27% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $0.62 | +28,885.51% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $52 | $10.30 | +404.85% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $20.52 | +299.61% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $20.50 | +134.15% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $5.00 | +12,900.00% | 1 | Nov 8, 2017 |
Corcept Therapeutics
Jan 23, 2026
Maintains: Buy
Price Target: $99 → $100
Current: $39.97
Upside: +150.19%
Ventyx Biosciences
Jan 8, 2026
Downgrades: Hold
Price Target: $16 → $14
Current: $13.97
Upside: +0.21%
Veru Inc.
Dec 18, 2025
Initiates: Buy
Price Target: $25
Current: $2.29
Upside: +991.70%
Madrigal Pharmaceuticals
Nov 13, 2025
Maintains: Buy
Price Target: $526 → $587
Current: $464.71
Upside: +26.32%
Viking Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $106 → $107
Current: $29.00
Upside: +268.97%
Sagimet Biosciences
Oct 2, 2025
Maintains: Buy
Price Target: $28
Current: $5.06
Upside: +453.36%
Inventiva
Sep 30, 2025
Maintains: Buy
Price Target: $20
Current: $6.17
Upside: +224.15%
Celldex Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $62
Current: $22.97
Upside: +169.92%
Travere Therapeutics
Apr 10, 2025
Maintains: Buy
Price Target: $45 → $47
Current: $27.82
Upside: +68.94%
Rani Therapeutics Holdings
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $1.24
Upside: +625.81%
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $1.11
Upside: +260.36%
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $67.78
Upside: +31.31%
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.03
Upside: +676.70%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $3.84
Upside: +342.71%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $3.24
Upside: -38.27%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $0.62
Upside: +28,885.51%
Aug 5, 2022
Downgrades: Hold
Price Target: $52
Current: $10.30
Upside: +404.85%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $20.52
Upside: +299.61%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $20.50
Upside: +134.15%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $5.00
Upside: +12,900.00%